|
XIV
INTERNATIONAL SYMPOSIUM ON
DRUGS
AFFECTING LIPID METABOLISM
SEPTEMBER
9-12, 2001
NEW YORK HILTON & TOWERS
SYMPOSIA
Acute
Coronary Syndrome: Role of Statin Therapy
Supported in part by an unrestricted educational
grant from
Pfizer Inc.
Advantages of the Multifactorial Risk Approach
in
Medical Practice
Supported in part by an unrestricted educational
grant from
Merck & Co., Inc. (MSD)
New Options in Lipid Management: Can We Extend
the
Benefits of Current Therapy?
Supported in part by an unrestricted educational
grant from
AstraZeneca Pharmaceuticals LP
Novel Pathways for Optimizing Lipid Management
Supported in part by an unrestricted educational
grant from
Merck/Schering-Plough Pharmaceuticals and
Schering-Plough International
Reducing Heart Disease Risk in Subgroups: A
Universal Imperative for the 21st Century
Supported in part by an unrestricted educational
grant from
Bristol-Myers Squibb Company
The Role of HDL Cholesterol in CHD Protection
Supported in part by an unrestricted educational
grant from
Groupe Fournier
Treating to Target: Bridging the Gap Between
Theory
and Practice
Supported in part by an unrestricted educational
grant from
Bayer Corporation and Bayer AG
What is Best Practice for Optimal Outcomes
in
Global Risk Reduction?
Supported in part by an unrestricted educational
grant from
Kowa Company LTD
The
Scientific Program will also include:
A) Workshops of Invited Lectures and Selected
Oral Communications (The Program Committee
will choose the best submitted abstracts to
be included as Oral Communications in the
Workshops)
B) Sessions of Oral Communications
C) Sessions of Posters
D) Case Studies
E) Lunch Sessions
1. "Novel Pathways to Optimizing Lipid
Management"
2. "Ethical Considerations for Clinical
Trials Studying Pharmacogenetics and Genetic
Susceptibility to CHD" |
|
